Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Post by farmerjaneon Mar 16, 2015 12:39pm
223 Views
Post# 23525798

Today's Announcement Explore selling assets

Today's Announcement Explore selling assetsHave to say folks I was right, never was the plan to do licensing agreements, played that one for two or three years. I said in the past many times that this was a front and not  the true company agenda. I think the outcome is already known by the bod, just a matter of time to playout. The company pulled their Corporate presentations off their Website a couple of weeks ago, told me that those were done and the Company headed in a different direction....No Sanfrancisco.....

This is the toughest time right now sitting on pins and needles, waiting to see the outcome. I called the outright sale a few years back, I just hope we are not underminded by any foul play. Other than quarterly reports and attending BioConferences PR's over the last few years we have really been restricted to information given to shareholders. Only the insiders and advisors will have clear ensight to what they have and what it is worth.  I have pointed out many times in the past why this was the case.

Good luck everyone !!!




Bullboard Posts